Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT05890911
Enrolling by invitation Observational

The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.

NCT05890911 · tracked via the Priya Life Science Poland tracker
Sponsor
Wroclaw Medical University
Phase
Observational
Started
2023-06-01
Last updated
2026-08-31

Condition(s) studied

Sleep ApneaSleep-Disordered Breathing

Investigational drug(s) / intervention(s)

PolysomnographyBlood dopamine level measurementGenetical test

Polysomnography: Each of the patients will undergo polysomnography

Blood dopamine level measurement: In each of the patients blood dopamine level will be measured

Genetical test: Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).

Study summary

The participants in the study will be adult patients with suspected sleep-disordered breathing. A one-night polysomnography will be performed using the NOXA1 device (NOX Medical, Reykjavík, Iceland). During the polysomnographic examination, sleep, breathing, heart rate and activity of the masticatory muscles will be recorded. Blood sample will be taken from each of the participants qualified to the study and control group to determine the level of dopamine and used to perform genetic tests of selected single nucleotide polymorphisms occurring within the genes regulating the concentration of dopamine and genes encoding dopamine receptors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * age between 18 and 80 years old * suspicion of sleep-disordered breathing Exclusion Criteria: * age under 18 * age over 80 * severe disorders and systemic diseases (including genetical disorders) * neurological disorders * active inflammations * active cancer * severe mental disorders and retardation (including genetical) * taking drugs that could falsify polysomnography * confirmed alcoholism * drug addiction * pregnancy and breast feeding * treatment using or dependence on any painkillers and/or drugs and substances that may affect nervous, muscular and respiratory system functions * lack of consent to participate in the study

Primary outcome measure(s)

  • Relationship between sleep-disordered breathing and blood dopamine level. — June 1, 2023 - December 31, 2023
    Each participant will undergo blood test focusing on the level of dopamine.

Trial sites (1)

FacilityCityRegionStatus
Wroclaw Medical Uniwesity Wroclaw Poland

More Wroclaw Medical University trials in Poland

Effects of Repletion of Sodium Chloride on Natriuresis, Blood Pressure, and Neurohormonal Activity in Patients With Chronic Heart Failure With Reduced Ejection Fraction Starting soon
Comparison of Three Types of Distal Arteriovenous Fistulas: SBAVF, RCAVF, and RCAVF With Venous Branch Patch. Recruiting
Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study Recruiting
Bruxism Induced by Obstructive Sleep Apnoea. Starting soon
Long-term Observation of Ophthalmic Changes in Patients With Obstructive Sleep Apnea Active, not recruiting

Other trials for the same condition

Long-term Observation of Ophthalmic Changes in Patients With Obstructive Sleep Apnea Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05890911 on ClinicalTrials.gov ↗ ← All trials in Poland